2 results match your criteria: "China Affiliated Hospital of Shanxi University of Chinese Medicine Taiyuan 030024[Affiliation]"
[Meta-analysis and GRADE evaluation of Guanxinning Tablets in treatment of angina pectoris of coronary heart disease].
Zhongguo Zhong Yao Za Zhi
January 2023
Shanxi University of Chinese Medicine Jinzhong 030619, China Affiliated Hospital of Shanxi University of Chinese Medicine Taiyuan 030024, China.
This study aims to evaluate the efficacy and safety of Guanxinning Tablets+conventional western medicine in the treatment of angina pectoris of coronary heart disease, and provide evidence-based references for clinical medication. Retrieved from CNKI, Wanfang, VIP, SinoMed, PubMed, EMbase, Cochrane Library, randomized controlled trial(RCT) about Guanxinning Tablets for the treatment of angina pectoris of coronary heart disease from the inception to April 2022 were collected. After literature screening and data extraction, the bias risk assessment tool recommended by the Cochrane evaluation manual handbook 5.
View Article and Find Full Text PDFArticle Synopsis
- - The study uses advanced mass spectrometry techniques to investigate how Chaiqin Ningshen Granules (CNG) affect the metabolism of insomnia rats, specifically focusing on a liver depression syndrome model induced by parachlorophenylalanine (PCPA).
- - By analyzing the hippocampus of the rats, the research finds that CNG significantly improves symptoms of insomnia, enhances neurotransmitter levels like serotonin and GABA, and identifies 27 potential biomarkers associated with insomnia.
- - The metabolic pathway analysis indicates that CNG and estazolam influence multiple metabolic pathways, suggesting their effectiveness in alleviating insomnia through the regulation of key metabolites.